|Bid||37.76 x 2200|
|Ask||37.75 x 2200|
|Day's Range||37.67 - 38.58|
|52 Week Range||27.88 - 40.97|
|Beta (5Y Monthly)||0.73|
|PE Ratio (TTM)||14.96|
|Earnings Date||Oct 27, 2020 - Nov 02, 2020|
|Forward Dividend & Yield||1.52 (3.96%)|
|Ex-Dividend Date||Jul 30, 2020|
|1y Target Est||41.85|
Both Inovio and BionNTech announced that they are making headway in their coronavirus vaccine trials, and will be able to meet deadlines toward the end of the year or a the start of 2021. Yahoo Finance’s Anjalee Khemlani breaks down the latest news about the coronavirus on The Final Round.
Latest news and updates and the global coronavirus pandemic.
Dow component Pfizer Inc. (PFE) and junior partner BioNTech SE (BNTX) have chosen their BNT162 mRNA-based vaccine candidate for advanced trials, following positive results that raise hopes for a COVID-19 vaccine. While speculators chase volatile BioNTech shares, Pfizer could emerge as a big winner in the vaccine wars, potentially lifting the chronically underperforming stock to a new high. Pfizer shareholders will also sleep better at night, with the smaller stock slicing through massive trading ranges since it took off for the heavens in March.